Review commonly discussed GLP-1 options and their different FDA-labeled uses. Product availability is not implied. Enrollment is not yet open.
These products are shown only for education. Display does not mean Eternal Springs currently offers or can obtain a product. Indication, eligibility, dose, supply and prescribing decisions belong to a licensed clinician.
A once-daily oral maintenance option for eligible adults. Treatment starts at a lower dose and is gradually increased under clinician direction.
A once-weekly prescription injection for chronic weight management in eligible patients.
A once-weekly prescription treatment for chronic weight management in eligible adults.
Approved for adults with type 2 diabetes. Its indication differs from Wegovy, so diagnosis and clinician judgment matter.
Approved to improve blood sugar control in eligible adults with type 2 diabetes. Its indication differs from Zepbound.
Review weight history, medical conditions, medications, goals and potential contraindications.
A licensed clinician determines whether a prescription option is medically appropriate.
Healthy eating guidance and low-, moderate- or higher-intensity exercise pathways support the plan.
Track progress, tolerability, strength and health—not only the number on the scale.
Prescription is not guaranteed. A licensed clinician must evaluate eligibility, indication, health history, contraindications and potential interactions.
Do not combine GLP-1 products. Patients should not use semaglutide- or tirzepatide-containing products together or take more than prescribed. Individual warnings and instructions apply.
Images are educational. Product appearance, packaging and availability may change. The tablet artwork is an illustration, not a dispensing photograph or actual-size representation.
Read official labeling. Review the current FDA prescribing information for Wegovy, Zepbound, Ozempic and Mounjaro.
View the patient process →